Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Read more about Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Read more about IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Read more about APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Read more about KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice.
Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Read more about Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy.
Development of a stress response therapy targeting aggressive prostate cancer. Read more about Development of a stress response therapy targeting aggressive prostate cancer.
An OX40/OX40L interaction directs successful immunity to hepatitis B virus. Read more about An OX40/OX40L interaction directs successful immunity to hepatitis B virus.
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. Read more about Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
Charting the "unknown unknowns" of cancer progression. Read more about Charting the "unknown unknowns" of cancer progression.
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Read more about A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
